We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Genetic Technologies Ltd (GENE) ADR Each Representing 30 Ord Shares SPON

Sell:$0.77 Buy:$0.77 Change: No change
Market closed |  Prices as at close on 16 October 2024 | Switch to live prices |
Sell:$0.77
Buy:$0.77
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 16 October 2024 | Switch to live prices |
Sell:$0.77
Buy:$0.77
Change: No change
Market closed |  Prices as at close on 16 October 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor

Contact details

Address:
Suite 7, Level 1, 321 Chapel Street
MELBOURNE
3181
Australia
Telephone:
+61 (3) 94151135
Website:
https://www.gtglabs.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GENE
ISIN:
US37185R4065
Market cap:
$3.65 million
Shares in issue:
132.22 million
Sector:
Life Sciences Tools & Services
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Simon Morriss
    Chief Executive Officer
  • Mark Ziirsen
    Chief Financial Officer, Company Secretary
  • Kevin Camilleri
    Chief Executive Officer - EasyDNA
  • Richard Allman
    Chief Scientific Officer
  • Carl Stubbings
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.